A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens

Psychopharmacology

Volumn 167, Issue 3, 2003, Pages 315-323

  Li, Zhu ^a,b   Ichikawa, Junji ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Acetylcholine; Dopamine; Loxapine; Serotonin; Thioridazine; Ziprasidone

Indexed keywords

ACETYLCHOLINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LOXAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A ANTAGONIST; SEROTONIN 2A RECEPTOR; THIORIDAZINE; ZIPRASIDONE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CATALEPSY; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

EID: 0038174604     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1418-x     Document Type: Article

References (53)

1. 2 receptors: an autoradiographic analysis in ray brain. Brain Res Bull 16:517-525
2. Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A (1984) Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci 35:1885-1893
3. 2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophr Res 15:153-154
4. Bonaccorso S, Meltzer H, Li Z, Dai J, Alboszta A, Ichikawa J (2002) SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 27:430-441
5. Carnahan RM, Lund BC, Perry PJ (2001) Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 21:717-730
6. Costall B, Naylor RJ (1973) Neuroleptic and non-neuroleptic catalepsy. Arzneimittelforschung 23:674-683
7. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites. Eur J Pharmacol 55:215-218
8. DePaulo J Jr, Ayd F (1982) Loxapine: fifteen years' clinical experience. Psychosomatics 23:261-271
9. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
10. Glazer W (1999) Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry 60:42-46
11. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296-304
12. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531
13. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002a) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neupsychopharmacology 26:325-339
14. Ichikawa J, Dai J, Meltzer HY (2002b) 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 939:34-42
15. Ichikawa J, Chung YC, Li Z, Dai J, Meltzer HY (2002c) Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 958:176-184
16. 2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br J Pharmacol 124:1550-1556
17. 2 receptor occupancy. Arch Gen Psychiatry 55:666-668
18. 2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 15:562-566
19. 2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 154:1525-1529
20. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140:173-184
21. Kuroki T, Meltzer HY, Icikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781
22. 2A receptor antagonism potentates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157-162
23. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 131:57-63
24. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835
25. Meltzer HY (1995) The concept of atypical antipsychotics. In: den Boer JA, Westenberg HGM, van Praag HM (eds) Advances in the neurobiology of schizophrenia, vol 1. Wiley, Sussex, pp 265-273
26. 2 receptor occupancy and the action of clozapine: does it make a difference to add a neuroleptic? Biol Psychiatry 46:144-149
27. Meltzer HY, Jayathilake K (1999) Low-dose loxapine in the treatment of schizophrenia: is it more effective and more atypical than standard-dose loxapine? J Clin Psychiatry 60:47-51
28. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognition in schizophrenia. Schizophr Bull 25:233-256
29. Meltzer HY, Sachar EJ, Franz AG (1975) Dopamine antagonism by thioridazine in schizophrenia. Biol Psychiatry 10:53-57
30. 2 pKi values. J Pharmacol Exp Ther 251:238-246
31. Miller RJ, Hiley CR (1976) Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines: relationship to drug induced parkinsonism. Naunyn Schmiedeberg's Arch Pharmacol 292:289-293
32. Moore DF (1975) Treatment of acute schizophrenia with loxapine succinate (Loxitane) in a controlled study with chlorpromazine. Curr Ther Res Clin Exp 18:172-180
33. 35-S]GTP gammaS binding study. Eur J Pharmacol 355:245-256
34. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
35. 2C receptor. Psychopharmacology 126:234-240
36. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York
37. 2 binding affinity. Neuropsychopharmacology 1:101-107
38. 2C receptor antagonist. Br J Pharmacol 126:572-574
39. 1A receptor activation contributes to ziprasidone-induced dopamine release in the prefrontal cortex. Biol Psychiatry 48:229-237
40. 1C receptors. J Pharmacol Exp Ther 260:1361-1365
41. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
42. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368
43. Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, Baba A, Matsuda T (2000) Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 129:1028-1034
44. Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235:60-64
45. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drug: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73
46. Schwartz JT, Brotman AW (1992) A clinical guide to antipsychotic drugs. Drugs 44:981-992
47. Seeman MV (1981) Pharmacological features and effects of neuroleptics. Can Med Assoc J 125: 821-826
48. 2 receptor subtypes. J Psychiatr Neurosci 21:29-34
49. 1A receptor activation. Neuropsychopharmacology 21:622-631
50. 2 receptors. J Pharmacol Exp Ther 266:1374-1384
51. Tanda G, Carboni E, Frau R, Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 115:285-288
52. 2 receptors of normal human brain in vitro. Eur J Pharmacol 143:279-282
53. Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T (2002) Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. Synapse 46:32-37